Kayakalp Global is revolutionizing autoimmune skin disorder treatment in India, focusing on root causes rather than cosmetic solutions.

Boehringer Ingelheim set to receive EUR 90 million as upfront payment, along with milestone payments and tiered royalties.

Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company targeting rare diseases, was spotlighted in a July 10 Zacks Small-Cap Research repo ...

One of the more serious side effects from immune checkpoint inhibitor (ICI) therapies for cancer is new-onset or worsened ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Bristol-Myers Squibb Company recently updated its ...

Which of the statements about the use of tumor necrosis factor inhibitors for managing rheumatic disorders are correct?

LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

LEO is claiming global commercial rights to Spevigo for GPP, but will also collaborate with Boehringer on potential follow-up ...